Kei Fukami - Search Results

Year	Number of Results
2004	1
2005	3
2007	5
2008	7
2009	13
2010	8
2011	7
2012	8
2013	12
2014	15
2015	12
2016	6
2017	10
2018	8
2019	5
2020	10
2021	14
2022	7
2023	11
2024	4

1

Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus.

Shibata R, Taguchi K, Kaida Y, Fukami K. Shibata R, et al. Among authors: fukami k. Clin Exp Nephrol. 2023 Jan;27(1):44-53. doi: 10.1007/s10157-022-02277-y. Epub 2022 Sep 17. Clin Exp Nephrol. 2023. PMID: 36114995 Free PMC article. Clinical Trial.

2

Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.

Ogata H, Fukagawa M, Hirakata H, Kagimura T, Fukushima M, Akizawa T; LANDMARK Investigators and Committees. Ogata H, et al. JAMA. 2021 May 18;325(19):1946-1954. doi: 10.1001/jama.2021.4807. JAMA. 2021. PMID: 34003226 Free PMC article. Clinical Trial.

3

RAGE signaling regulates the progression of diabetic complications.

Taguchi K, Fukami K. Taguchi K, et al. Among authors: fukami k. Front Pharmacol. 2023 Mar 16;14:1128872. doi: 10.3389/fphar.2023.1128872. eCollection 2023. Front Pharmacol. 2023. PMID: 37007029 Free PMC article. Review.

4

New insights regarding clinical goals for preventing rapid decline in renal function in Japanese population.

Taguchi K, Fukami K. Taguchi K, et al. Among authors: fukami k. Hypertens Res. 2023 May;46(5):1157-1159. doi: 10.1038/s41440-023-01221-1. Epub 2023 Feb 21. Hypertens Res. 2023. PMID: 36810624 No abstract available.

5

Uremic Toxin-Targeting as a Therapeutic Strategy for Preventing Cardiorenal Syndrome.

Taguchi K, Elias BC, Brooks CR, Ueda S, Fukami K. Taguchi K, et al. Among authors: fukami k. Circ J. 2019 Dec 25;84(1):2-8. doi: 10.1253/circj.CJ-19-0872. Epub 2019 Dec 11. Circ J. 2019. PMID: 31827008 Free article. Review.

6

Role of AGEs-RAGE system in cardiovascular disease.

Fukami K, Yamagishi S, Okuda S. Fukami K, et al. Curr Pharm Des. 2014;20(14):2395-402. doi: 10.2174/13816128113199990475. Curr Pharm Des. 2014. PMID: 23844818 Review.

7

Receptor for advanced glycation endproducts and progressive kidney disease.

Fukami K, Taguchi K, Yamagishi S, Okuda S. Fukami K, et al. Curr Opin Nephrol Hypertens. 2015 Jan;24(1):54-60. doi: 10.1097/MNH.0000000000000091. Curr Opin Nephrol Hypertens. 2015. PMID: 25470016 Review.

8

Carnitine Deficiency in Intensive Care Unit Patients Undergoing Continuous Renal Replacement Therapy.

Fukami K, Taguchi K. Fukami K, et al. JMA J. 2024 Jan 15;7(1):77-78. doi: 10.31662/jmaj.2023-0200. Epub 2023 Dec 27. JMA J. 2024. PMID: 38314422 Free PMC article. No abstract available.

9

Role of AGEs in diabetic nephropathy.

Fukami K, Yamagishi S, Ueda S, Okuda S. Fukami K, et al. Curr Pharm Des. 2008;14(10):946-52. doi: 10.2174/138161208784139710. Curr Pharm Des. 2008. PMID: 18473844 Review.

10

Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.

Taguchi K, Fukami K, Elias BC, Brooks CR. Taguchi K, et al. Among authors: fukami k. Toxins (Basel). 2021 May 19;13(5):361. doi: 10.3390/toxins13050361. Toxins (Basel). 2021. PMID: 34069405 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

133 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Results by year